search
Back to results

Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration

Primary Purpose

End-stage Renal Disease

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
HDF NaCl
Hemodialysis
Standard Predilution Hemodiafiltration
Sponsored by
EXcorLab GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for End-stage Renal Disease focused on measuring Maintenance hemodialysis or hemodiafiltration, >18 years, Stable condition

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • End-stage renal disease
  • Maintenance hemodialysis or hemodiafiltration for more than 3 months
  • Stable clinical condition
  • > 18 years

Exclusion Criteria:

  • Life expectancy less than 1 year
  • Pregnancy
  • Active infectious disease

Sites / Locations

  • Dialysis Center Elsenfeld

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

HDF NaCl, Then HD, Then Standard Pre-HDF

HD, Then Standard Pre-HDF, Then HDF NaCl

Standard Pre-HDF, Then HDF NaCl, Then HD

Arm Description

Participants first receive hemodiafiltration with infusion of 5 M NaCl for 4 hours. After a washout period of 1 week, they then receive 4 hours of bicarbonate hemodialysis. After another washout period of 1 week, they reveive 4 hours of standard predilution hemodiafiltration.

Participants first receive bicarbonate hemodialysis for 4 hours. After a washout period of 1 week, they then receive 4 hours of standard predilution hemodiafiltration. After another washout period of 1 week, they reveive 4 hours of hemodiafiltration with infusion of 5 M NaCl.

Participants first receive standard predilution hemodiafiltration for 4 hours. After a washout period of 1 week, they then receive hemodiafiltration with infusion of 5 M NaCl 4 hours of. After another washout period of 1 week, they reveive 4 hours of bicarbonate hemodialysis.

Outcomes

Primary Outcome Measures

Removal of Para-cresylsulfate
Determination of reduction ratio, which is the ratio of a solute concentration in plasma at baseline and at the end of the intervention
Removal of Indoxylsulfate
Determination of the reduction ratio, which is the ratio of a solute concentration in plasma at baseline and at the end of the intervention

Secondary Outcome Measures

Plasma Sodium Concentrations
Maximum arterial sodium concentrations
Hemocompatibility
Maximum free hemoglobin in plasma, which indicates hemolysis. Hemoglobin is released into plasma in case of red blood cell destruction.

Full Information

First Posted
August 10, 2013
Last Updated
July 27, 2018
Sponsor
EXcorLab GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT01923961
Brief Title
Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration
Official Title
Impact of an Increased Sodium Chloride Concentration in the Infusion Fluid of Predilution Hemodiafiltration on the Removal of Protein-Bound Uremic Toxins
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
August 2013 (Actual)
Primary Completion Date
March 30, 2015 (Actual)
Study Completion Date
August 10, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
EXcorLab GmbH

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
An increase of the free fraction may allow a better removal of of protein-bound uremic toxins during dialysis. During predilution hemodiafiltration, the sodium chloride (NaCl) concentration will be increased in the infusion fluid at a target NaCl concentration and the effect on the removal of protein-bound toxins will be determined. Comparisons will be made to standard hemodialysis and hemodiafiltration.
Detailed Description
Eight maintenance dialysis patients will be enrolled in a prospective, randomized, crossover trial. HD will be compared with online pre-dilution HDF and HDF at increased plasma ionic strength. The ionic strength will be increased using an infusion fluid with hypertonic [Na+] by isovolumetric adding of a 5000 mmol/L NaCl solution. Blood and dialysate flowrates (250 and 575 mL/min, respectively), treatment time (240 min), and high-flux dialyser (surface area 2.1 sqm, PUREMA H) will be always kept identical. Anticoagulation with standard or fractionated heparin will be unchanged adopted from the patients' routinely used regimen. In both HDF modes, the infusion flow rate will be 125 mL/min. In HDF at increased plasma ionic strength, the infusate [Na+] will be adjusted to approach 240 mmol/L in plasma entering the dialyser and the dialysate [Na+] will be set at the technically feasible minimum of 130 mmol/L. Blood samples will be drawn from the arterial and venous blood lines and, if applicable, from the blood tubing connecting the two dialyzers at 0, 15, 30, 60, 120, 180, and 240 min. Samples at 240 min will be drawn after reducing the blood flow rate to 50 mL/min for 30 s and the dialysate flow turned off. A fraction of the spent dialysate will be continuously collected. Removal of the free and total fraction of para-cresyl sulfate and indoxyl sulfate will be determined by reduction ratios, dialytic clearances and mass in dialysate Hemocompatibility will be assessed by WBC and platelet counts, free Hb, LDH, C5a and TAT. [Na+] will be monitored in both arterial (i.e. before NaCl infusion) and venous blood of the extracorporeal system.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End-stage Renal Disease
Keywords
Maintenance hemodialysis or hemodiafiltration, >18 years, Stable condition

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
8 (Actual)

8. Arms, Groups, and Interventions

Arm Title
HDF NaCl, Then HD, Then Standard Pre-HDF
Arm Type
Experimental
Arm Description
Participants first receive hemodiafiltration with infusion of 5 M NaCl for 4 hours. After a washout period of 1 week, they then receive 4 hours of bicarbonate hemodialysis. After another washout period of 1 week, they reveive 4 hours of standard predilution hemodiafiltration.
Arm Title
HD, Then Standard Pre-HDF, Then HDF NaCl
Arm Type
Experimental
Arm Description
Participants first receive bicarbonate hemodialysis for 4 hours. After a washout period of 1 week, they then receive 4 hours of standard predilution hemodiafiltration. After another washout period of 1 week, they reveive 4 hours of hemodiafiltration with infusion of 5 M NaCl.
Arm Title
Standard Pre-HDF, Then HDF NaCl, Then HD
Arm Type
Experimental
Arm Description
Participants first receive standard predilution hemodiafiltration for 4 hours. After a washout period of 1 week, they then receive hemodiafiltration with infusion of 5 M NaCl 4 hours of. After another washout period of 1 week, they reveive 4 hours of bicarbonate hemodialysis.
Intervention Type
Procedure
Intervention Name(s)
HDF NaCl
Other Intervention Name(s)
Hemodialysis, Standard Predilution Hemodiafiltration
Intervention Type
Procedure
Intervention Name(s)
Hemodialysis
Other Intervention Name(s)
Standard Predilution Hemodiafiltration, HDF NaCl
Intervention Type
Procedure
Intervention Name(s)
Standard Predilution Hemodiafiltration
Other Intervention Name(s)
HDF NaCl, Hemodialysis
Primary Outcome Measure Information:
Title
Removal of Para-cresylsulfate
Description
Determination of reduction ratio, which is the ratio of a solute concentration in plasma at baseline and at the end of the intervention
Time Frame
4 hours
Title
Removal of Indoxylsulfate
Description
Determination of the reduction ratio, which is the ratio of a solute concentration in plasma at baseline and at the end of the intervention
Time Frame
4 hours
Secondary Outcome Measure Information:
Title
Plasma Sodium Concentrations
Description
Maximum arterial sodium concentrations
Time Frame
4 hours
Title
Hemocompatibility
Description
Maximum free hemoglobin in plasma, which indicates hemolysis. Hemoglobin is released into plasma in case of red blood cell destruction.
Time Frame
4 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: End-stage renal disease Maintenance hemodialysis or hemodiafiltration for more than 3 months Stable clinical condition > 18 years Exclusion Criteria: Life expectancy less than 1 year Pregnancy Active infectious disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Detlef H Krieter, MD
Organizational Affiliation
Wuerzburg University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dialysis Center Elsenfeld
City
Elsenfeld
State/Province
Bavaria
ZIP/Postal Code
63820
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration

We'll reach out to this number within 24 hrs